This document provides a comprehensive overview of Leishmaniasis, a globally prevalent infectious disease caused by obligate intracellular Leishmania parasites. It details the disease's transmission by sandflies, its increasing presence in non-endemic areas like Germany due to climate change, and its varied clinical manifestations in humans and animals. The three main forms of human leishmaniasis—visceral, cutaneous, and mucocutaneous—are described, highlighting their specific symptoms, causative agents, and prognosis, including the high mortality rate of untreated visceral leishmaniasis. The text also covers the detailed life cycle and pathogenesis of the parasite, diagnostic methods ranging from direct parasite detection to serological tests, and a range of therapeutic approaches, emphasizing that complete cure is often elusive. Finally, it discusses important prophylactic measures, including vector control and dog vaccination, and ongoing research efforts.
Summarizing Leishmaniasis: A Comprehensive Overview
Introduction: A Global Infectious Disease
Leishmaniasis is a worldwide infectious disease affecting both humans and animals, caused by obligate intracellular protozoan parasites of the Leishmania genus.
Predominantly found in tropical regions, the Mediterranean, and Asia, its spread, particularly of sandfly vectors, is increasing in countries like Germany, linked to climate change and globalization.
The pathogen Leishmania donovani was discovered by William B. Leishman and Charles Donovan between 1900 and 1903.
Transmission and Epidemiology
The infection is transmitted by sandflies (Phlebotominae); their populations, once reduced by insecticides, have rebounded, leading to increasing cases.
The disease is endemic in 98 countries, causing approximately 1 million cutaneous and 50,000-90,000 visceral infections annually.
Dogs, especially in the Mediterranean region, show high infection rates (e.g., up to 80% in Sicily), serving as primary reservoirs.
Forms of Human Leishmaniasis (ICD-10 Classification)
Visceral Leishmaniasis (Kala-Azar): Affects internal organs (liver, spleen), often caused by L. donovani or L. infantum. Historically spread from East Africa to India, it also occurs in Europe and South America. Without treatment, it is fatal in about 95% of cases.
Cutaneous Leishmaniasis (Baghdad Boil): Primarily affects the skin, forming itchy nodules and non-painful ulcers. While often self-healing within six to twelve months, it can leave disfiguring scars. The diffuse form, however, does not heal without treatment.
Mucocutaneous Leishmaniasis (Espundia): Known in South America, it affects both skin and mucous membranes, causing severe, destructive lesions that do not heal spontaneously.
Veterinary Medicine
Domestic dogs are the most commonly affected animals and main reservoirs. Cases are also described in cats, rodents, cattle, and horses.
The parasite requires two hosts: a biting insect (sandfly) where the flagellated promastigote form develops, and a vertebrate (including humans) where the non-flagellated amastigote form resides within macrophages.
Pathogenesis and Immune Response
After infection, Leishmania multiply in sandfly guts, transform, and are transmitted to mammals during bites. They infect macrophages, multiplying and spreading through the lymphatic system, bone marrow, spleen, and liver.
Incubation periods vary widely from one month to seven years.
The disease course depends on the host's immune response: a strong cellular (T1-helper cell) response leads to resistance, while a humoral response can lead to disease progression, organ damage, and potentially death.
Clinical Presentation and Diagnosis
Leishmaniasis presents with highly variable symptoms due to its ability to affect almost all organ systems.
In dogs, common symptoms include symmetric hair loss, skin ulcers, and nodules. In cats, ulcerative and nodular skin changes dominate, along with eye diseases, anemia, and kidney damage.
Diagnosis can be challenging. Direct parasite detection is done via microscopic examination of tissue samples or PCR (highly sensitive). Indirect methods involve serological antibody tests (e.g., ELISA), though false negatives are possible in early stages.
Therapy
Complete cure is often not possible; treatment focuses on pathogen elimination and strengthening the host's cellular immunity.
Key drugs include N-Methylglucamine antimonate (often first choice), Sodium Stibogluconate, Pentamidine, and Miltefosin (an oral option approved for humans and dogs).
Allopurinol, various antibiotics (e.g., Amphotericin B, Paromomycin), and immunotherapy (recombinant Interferon) are also used or being investigated.
Prophylaxis
Preventing sandfly bites is crucial, using repellents like pyrethroids.
Vaccines for dogs, such as Canileish (since 2011) and LetiFend (since 2019), aim to reduce infection and disease risk.
Research
Significant contributions to understanding Leishmaniasis were made by parasitologist Ralph Lainson.
The "Drug Search for Leishmaniasis" project on World Community Grid, launched in 2011, focuses on discovering new drugs against resistant strains of the disease.